Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




May
18
Today In Oncology
Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer
Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age
FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2 Positive Early Breast Cancer
Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience
Advanced Prostate Cancer Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo